Mexolan

Meloxicam, the active ingredient in Mexolan, is a nonsteroidal anti‑inflammatory drug (NSAID) presented as an oral tablet for oral use. It is indicated for the relief of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute musculoskeletal conditions.

GNH USA supplies Mexolan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam acts on inflammatory pathways to reduce pain and swelling in several musculoskeletal disorders.

Osteoarthritis: alleviates joint pain and improves mobility. Rheumatoid arthritis: decreases inflammation and joint damage. Ankylosing spondylitis: reduces spinal stiffness and pain. Acute musculoskeletal pain: provides rapid analgesic effect.

Adverse reactions may occur with meloxicam therapy.

Common Side Effects: - Gastro‑intestinal discomfort or dyspepsia. - Headache. - Dizziness. - Mild skin rash. - Edema. - Elevated liver enzymes.

Serious or Rare Side Effects: - Gastro‑intestinal ulceration or bleeding. - Severe hepatic injury. - Renal impairment or failure. - Cardiovascular events such as myocardial infarction. - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome). - Anaphylaxis or severe hypersensitivity.

Before initiating therapy, consider the following precautions.

Renal function assessment: evaluate baseline kidney status. Hepatic monitoring: check liver enzymes periodically. Cardiovascular risk: use the lowest effective dose in patients with heart disease. Bleeding risk: avoid concomitant use with anticoagulants unless necessary. Hypersensitivity: discontinue if signs of severe allergic reaction appear. Store at ambient temperature: keep in the original container, protect from moisture and light.

Meloxicam can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: heightened gastrointestinal toxicity. - ACE inhibitors or ARBs: possible reduction in renal function. - Lithium: elevated serum lithium levels. - Methotrexate: enhanced toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance. - SSRIs or SNRIs: increased bleeding tendency. - Corticosteroids: additive gastrointestinal risk. - Antihypertensives: possible reduction in blood pressure control. - Oral hypoglycemics: may require dose adjustment.